Medical Condition News

RSS

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

Wear That You Care. Today is Rare Disease Day and 46NYC is helping raise awareness for an important cause – this time the drug development crisis facing the rare disease patient community worldwide.

28 Feb 2011

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Just in time for Heart Health Month, EcoNugenics introduces CIRCUTOL Cardiovascular Health Support. EcoNugenics has once again demonstrated excellence in being at the forefront of the latest developments in natural alternative health solutions.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Investing in adolescents can help reduce poverty, improve health, UNICEF report says

Additional investment in the world's 1.2 billion adolescents - 88 percent of whom live in the developing world - has the potential to help alleviate inequality and poverty, UNICEF said in its annual State of the World's Children report released on Friday, IRIN reports.

28 Feb 2011

Medunik to introduce novel orphan drugs to Canadians with rare diseases

Éric Gervais, Executive Vice-President of Medunik Canada, is proud to announce the Management Team of this recently created company. Medunik Canada is a Quebec pharmaceutical company with 60 employees and one unique mission - bring novel orphan drugs to Canadians with rare diseases.

28 Feb 2011

Despite FDA action, Deston still believes Auralgan as a safe and effective drug product

Deston Therapeutics LLC announced today that it is currently exploring its options to respond to a recent seizure of its Auralgan Otic Solution by the Federal Government and that it still believes that Auralgan is a safe and effective drug product.

28 Feb 2011

Researchers discover new mechanism of beta cell destruction not previously known

The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.

28 Feb 2011

Survey: 65% of patients in hospitals experience pain prevalence

Nearly two-thirds of the hospital in-patients who took part in a survey had experienced pain in the last 24 hours and 42% of those rated their pain as more than seven out of ten, where ten was the worst pain imaginable, according to the March issue of the Journal of Clinical Nursing.

28 Feb 2011

Affymetrix introduces new GeneChip miRNA 2.0 Array

Affymetrix, Inc. today launched the GeneChip miRNA 2.0 Array. This enhanced version of its best-in-class microRNA interrogation solution will support the research community's pursuit of personalized medicine by accelerating the identification of biomarkers and gene expression signatures associated with disease.

28 Feb 2011

New study: Free radicals play a key role in heart physiology

Fear of free radicals may be exaggerated, according to scientists from the Swedish medical university Karolinska Institutet. A new study, published in The Journal of Physiology, shows that free radicals act as signal substances that cause the heart to beat with the correct force.

28 Feb 2011

New national campaign to help reduce risk of pressure ulcers in hospital and post-acute care settings

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced the introduction of a new national campaign to help reduce the risk of pressure ulcers in hospital and post-acute care settings.

28 Feb 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

28 Feb 2011

QIAGEN, Epigenomics enter option agreement to commercialize colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnostics company, and QIAGEN today announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

From QIAGEN Manchester Limited 28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Specialty biopharmaceutical company Santarus, Inc.and biotech company Pharming Group NV today announced the receipt of a "refusal to file" letter from the U.S. Food and Drug Administration for the RHUCIN Biologics License Application submitted by Pharming.

28 Feb 2011

ABC program greatly reduces asthma-related ED visits in preschool children

Nearly one in eleven preschool children in the U.S. has been diagnosed with asthma and in some inner city neighborhoods, the figure is closer to one in seven. But, few asthma management programs are designed for parents of preschool children.

28 Feb 2011

Study: Radio-guided surgery effectively removes nodules in patients with lung cancer

Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques, Italian researchers report at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.

28 Feb 2011

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that fish oil may help combat cancer-related malnutrition.

28 Feb 2011

Medical Condition News

p53 gene blocks EMT essential to cancer metastasis

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Researchers to examine thrombolysis for treatment of DVT in leg

Investing in adolescents can help reduce poverty, improve health, UNICEF report says

Medunik to introduce novel orphan drugs to Canadians with rare diseases

Despite FDA action, Deston still believes Auralgan as a safe and effective drug product

Researchers discover new mechanism of beta cell destruction not previously known

Survey: 65% of patients in hospitals experience pain prevalence

Affymetrix introduces new GeneChip miRNA 2.0 Array

New study: Free radicals play a key role in heart physiology

New national campaign to help reduce risk of pressure ulcers in hospital and post-acute care settings

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

QIAGEN, Epigenomics enter option agreement to commercialize colorectal cancer blood test

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

ABC program greatly reduces asthma-related ED visits in preschool children

Study: Radio-guided surgery effectively removes nodules in patients with lung cancer

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News